PCI Biotech: Employee Stock Option Plan

Oslo, September 2, 2024 – PCI Biotech (OSE: PCIB) today announces that the Board of Directors has granted stock options to key employees.

In accordance with the authorization granted by the Annual General Meeting of Shareholders on May 24, 2024 and the remuneration policy adopted by the Annual General Meeting of Shareholders on May 28, 2021, the Board of Directors of PCI Biotech Holding ASA (“PCI Biotech”) has granted a total of 885,000 stock options to key employees. Each stock option entitles the holder to subscribe for or acquire (at PCI Biotech’s option) one share per option, at an exercise price of NOK 1.81, equal to the volume weighted average share price (VWAP) for the last 5 trading days prior to the grant date. The stock options are granted for no consideration and are subject to service-based vesting conditions, and the stock options will vest evenly over a vesting period of three years. The stock options expire in Q3 2029. Further information on the stock option program is described in PCI Biotech’s remuneration policy.